AC
FOLD

Athos Capital’s Amicus Therapeutics FOLD Stock Holding History

Athos Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1M Buy
695,500
+95,500
+16% +$1.37M 3.1% 10
2025
Q4 		$8.54M Buy
+600,000
New +$5.89M 3.27% 9

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Athos Capital's FOLD Position: Q1 2026 in Review

Athos Capital increased its Amicus Therapeutics (FOLD) stake by 16% in Q1 2026, buying an estimated $1.37M and bringing the position to 695,500 shares worth $10.1M. The position accounts for 3.1% of the portfolio, ranked #10.

Athos Capital first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Athos Capital held 695,500 shares of Amicus Therapeutics worth $10.1M as of Q1 2026.
  • Athos Capital bought 95,500 Amicus Therapeutics shares in Q1 2026, an estimated $1.37M.
  • Amicus Therapeutics made up 3.1% of Athos Capital's portfolio in Q1 2026, its #10 holding.
  • Athos Capital first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Athos Capital's 13F filing for Q1 2026, filed 13 May 2026.